Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism

Federico Biscetti, Giovanni Pecorini, Giuseppe Straface, Vincenzo Arena, Egidio Stigliano, Sergio Rutella, Franco Locatelli, Flavia Angelini, Giovanni Ghirlanda, Andrea Flex

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background/objectives: Cilostazol has been found to be effective for the treatment of intermittent claudication (IC). This compound has several beneficial effects on platelet aggregation, serum lipids and endothelial cells, but how these might relate to improvements in walking is not entirely understood. The aim of this work was to investigate the effects of cilostazol on angiogenic response in a murine model of peripheral ischemia and to clarify the underlying molecular mechanisms of that response. Methods: We studied ischemia-induced neovascularization in the ischemic hindlimb of cilostazol-treated and untreated control mice. Results: We found that the perfusion recovery was significantly improved in treated compared with control mice. Interestingly, there was a higher level of circulating endothelial progenitor cells (EPCs) in mice treated with cilostazol than in untreated mice. Furthermore, cilostazol administration resulted in upregulation of granulocyte colony-stimulating factor (G-CSF) and vascular endothelial growth factor (VEGF) in the ischemic muscle of treated mice. Finally, inhibiting VEGF activity significantly reduced cilostazol-induced angiogenesis. Conclusions: The results of this study show that cilostazol administration enhances collateral blood flow in the ischemic hindlimbs of mice through a VEGF-dependent mechanism. These data may help to explain the beneficial effects that this drug has on patients with peripheral arterial disease (PAD) and IC.

Original languageEnglish
Pages (from-to)910-916
Number of pages7
JournalInternational Journal of Cardiology
Volume167
Issue number3
DOIs
Publication statusPublished - Aug 10 2013

Fingerprint

Vascular Endothelial Growth Factor A
Ischemia
Intermittent Claudication
Hindlimb
Peripheral Arterial Disease
Granulocyte Colony-Stimulating Factor
cilostazol
Platelet Aggregation
Walking
Up-Regulation
Endothelial Cells
Perfusion
Lipids
Muscles
Serum
Pharmaceutical Preparations

Keywords

  • Angiogenesis
  • Cilostazol
  • Vascular endothelial growth factor
  • VEGF

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Biscetti, F., Pecorini, G., Straface, G., Arena, V., Stigliano, E., Rutella, S., ... Flex, A. (2013). Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism. International Journal of Cardiology, 167(3), 910-916. https://doi.org/10.1016/j.ijcard.2012.03.103

Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism. / Biscetti, Federico; Pecorini, Giovanni; Straface, Giuseppe; Arena, Vincenzo; Stigliano, Egidio; Rutella, Sergio; Locatelli, Franco; Angelini, Flavia; Ghirlanda, Giovanni; Flex, Andrea.

In: International Journal of Cardiology, Vol. 167, No. 3, 10.08.2013, p. 910-916.

Research output: Contribution to journalArticle

Biscetti, F, Pecorini, G, Straface, G, Arena, V, Stigliano, E, Rutella, S, Locatelli, F, Angelini, F, Ghirlanda, G & Flex, A 2013, 'Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism', International Journal of Cardiology, vol. 167, no. 3, pp. 910-916. https://doi.org/10.1016/j.ijcard.2012.03.103
Biscetti, Federico ; Pecorini, Giovanni ; Straface, Giuseppe ; Arena, Vincenzo ; Stigliano, Egidio ; Rutella, Sergio ; Locatelli, Franco ; Angelini, Flavia ; Ghirlanda, Giovanni ; Flex, Andrea. / Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism. In: International Journal of Cardiology. 2013 ; Vol. 167, No. 3. pp. 910-916.
@article{81abd4f9a38a475aa81ff3c8167e51f6,
title = "Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism",
abstract = "Background/objectives: Cilostazol has been found to be effective for the treatment of intermittent claudication (IC). This compound has several beneficial effects on platelet aggregation, serum lipids and endothelial cells, but how these might relate to improvements in walking is not entirely understood. The aim of this work was to investigate the effects of cilostazol on angiogenic response in a murine model of peripheral ischemia and to clarify the underlying molecular mechanisms of that response. Methods: We studied ischemia-induced neovascularization in the ischemic hindlimb of cilostazol-treated and untreated control mice. Results: We found that the perfusion recovery was significantly improved in treated compared with control mice. Interestingly, there was a higher level of circulating endothelial progenitor cells (EPCs) in mice treated with cilostazol than in untreated mice. Furthermore, cilostazol administration resulted in upregulation of granulocyte colony-stimulating factor (G-CSF) and vascular endothelial growth factor (VEGF) in the ischemic muscle of treated mice. Finally, inhibiting VEGF activity significantly reduced cilostazol-induced angiogenesis. Conclusions: The results of this study show that cilostazol administration enhances collateral blood flow in the ischemic hindlimbs of mice through a VEGF-dependent mechanism. These data may help to explain the beneficial effects that this drug has on patients with peripheral arterial disease (PAD) and IC.",
keywords = "Angiogenesis, Cilostazol, Vascular endothelial growth factor, VEGF",
author = "Federico Biscetti and Giovanni Pecorini and Giuseppe Straface and Vincenzo Arena and Egidio Stigliano and Sergio Rutella and Franco Locatelli and Flavia Angelini and Giovanni Ghirlanda and Andrea Flex",
year = "2013",
month = "8",
day = "10",
doi = "10.1016/j.ijcard.2012.03.103",
language = "English",
volume = "167",
pages = "910--916",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism

AU - Biscetti, Federico

AU - Pecorini, Giovanni

AU - Straface, Giuseppe

AU - Arena, Vincenzo

AU - Stigliano, Egidio

AU - Rutella, Sergio

AU - Locatelli, Franco

AU - Angelini, Flavia

AU - Ghirlanda, Giovanni

AU - Flex, Andrea

PY - 2013/8/10

Y1 - 2013/8/10

N2 - Background/objectives: Cilostazol has been found to be effective for the treatment of intermittent claudication (IC). This compound has several beneficial effects on platelet aggregation, serum lipids and endothelial cells, but how these might relate to improvements in walking is not entirely understood. The aim of this work was to investigate the effects of cilostazol on angiogenic response in a murine model of peripheral ischemia and to clarify the underlying molecular mechanisms of that response. Methods: We studied ischemia-induced neovascularization in the ischemic hindlimb of cilostazol-treated and untreated control mice. Results: We found that the perfusion recovery was significantly improved in treated compared with control mice. Interestingly, there was a higher level of circulating endothelial progenitor cells (EPCs) in mice treated with cilostazol than in untreated mice. Furthermore, cilostazol administration resulted in upregulation of granulocyte colony-stimulating factor (G-CSF) and vascular endothelial growth factor (VEGF) in the ischemic muscle of treated mice. Finally, inhibiting VEGF activity significantly reduced cilostazol-induced angiogenesis. Conclusions: The results of this study show that cilostazol administration enhances collateral blood flow in the ischemic hindlimbs of mice through a VEGF-dependent mechanism. These data may help to explain the beneficial effects that this drug has on patients with peripheral arterial disease (PAD) and IC.

AB - Background/objectives: Cilostazol has been found to be effective for the treatment of intermittent claudication (IC). This compound has several beneficial effects on platelet aggregation, serum lipids and endothelial cells, but how these might relate to improvements in walking is not entirely understood. The aim of this work was to investigate the effects of cilostazol on angiogenic response in a murine model of peripheral ischemia and to clarify the underlying molecular mechanisms of that response. Methods: We studied ischemia-induced neovascularization in the ischemic hindlimb of cilostazol-treated and untreated control mice. Results: We found that the perfusion recovery was significantly improved in treated compared with control mice. Interestingly, there was a higher level of circulating endothelial progenitor cells (EPCs) in mice treated with cilostazol than in untreated mice. Furthermore, cilostazol administration resulted in upregulation of granulocyte colony-stimulating factor (G-CSF) and vascular endothelial growth factor (VEGF) in the ischemic muscle of treated mice. Finally, inhibiting VEGF activity significantly reduced cilostazol-induced angiogenesis. Conclusions: The results of this study show that cilostazol administration enhances collateral blood flow in the ischemic hindlimbs of mice through a VEGF-dependent mechanism. These data may help to explain the beneficial effects that this drug has on patients with peripheral arterial disease (PAD) and IC.

KW - Angiogenesis

KW - Cilostazol

KW - Vascular endothelial growth factor

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84880923164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880923164&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2012.03.103

DO - 10.1016/j.ijcard.2012.03.103

M3 - Article

VL - 167

SP - 910

EP - 916

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 3

ER -